CompletedNot Applicable

Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients

South Korea2,044 participantsStarted 2023-10-26

Plain-language summary

The aim of this study is to evaluate the effectiveness and safety of the triple combination therapy of Zemidapa Tab. and Metformin in patients with type 2 diabete mellitus

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Double combination therapy (Metformin and a DPP-4 inhibitor other than Gemigliptin)
✓. Triple combination therapy (Metformin, a DPP-4 inhibitor other than Gemigliptin, and a SGLT-2 inhibitor)
✓. Triple combination therapy (Metformin, a DPP-4 inhibitor other than Gemigliptin, and Sulfonylurea \[SU\])

What they're measuring

change from baseline of HbA1c at 12 weeks

Timeframe: baseline, 12 weeks

Trial details

NCT IDNCT06495281

SponsorLG Chem

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-12-03

View on ClinicalTrials.gov More Type 2 Diabetes Mellitus trials